(NP (NP (NNS Changes)) (PP (IN in) (NP (NP (NP (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (NN T3)) (-RRB- -RRB-))) (JJ mononuclear) (NN leukocyte) (NN receptor) (NNS kinetics))) (PP-TMP (IN after) (NP-COOD (NP (NN T3) (NN administration)) (CC and) (NP (JJ multiple) (JJ cold-air) (NNS exposures)))) (. .))
(S (NP-SBJ (VBN Repeated) (JJ cold-air) (NNS exposures)) (VP (VBP increase) (NP (JJ human) (NP (NP (NN triiodothyronine)) (PRN (-LRB- -LRB-) (NP (CD T3)) (-RRB- -RRB-))) (NN plasma) (NN clearance) (NNS rates))) (. .))
(S (S (NP-SBJ (-NONE- *)) (VP (TO To) (VP (VB study) (NP (NP (DT the) (NN response)) (PP (IN of) (NP (NP (DT the) (JJ nuclear) (NN T3) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NN NT3R)) (-RRB- -RRB-)))) (PP (IN in) (NP (DT this) (NN condition))))))) (, ,) (NP-SBJ-36 (VBG binding) (NNS characteristics)) (VP (VBD were) (VP (VBN analyzed) (NP (-NONE- *-36)) (PP (IN in) (NP (JJ human) (NP (NP (JJ mononuclear) (NNS leukocytes)) (PRN (-LRB- -LRB-) (NP (NN MNL)) (-RRB- -RRB-))))))) (. .))
(S (PP (IN In) (NP (NN addition))) (, ,) (NP-SBJ-37 (PRP we)) (VP (VBD supplemented) (NP (NP (CD one) (NN group)) (PP (IN of) (NP (NNS individuals)))) (PP (IN with) (NP (NP (DT a) (RB daily) (JJ oral) (NN replacement) (NN dose)) (PP (IN of) (NP (NN T3))))) (S (NP-SBJ (-NONE- *-37)) (VP (TO to) (VP (VB isolate) (NP (NP (DT the) (NN influence)) (PP (IN of) (NP (NP-COOD (NP (NP (NN serum) (NN thyroxine)) (PRN (-LRB- -LRB-) (NP (NN T4)) (-RRB- -RRB-))) (CC and) (NP (NP (NN thyrotropin)) (PRN (-LRB- -LRB-) (NP (NN TSH)) (-RRB- -RRB-)))) (NNS levels))) (PP (IN on) (NP (NN receptor) (NNS kinetics)))))))) (. .))
(S (NP-SBJ-38 (DT The) (NNS subjects)) (VP (VBD were) (VP (VBN exposed) (NP (-NONE- *-38)) (PP (TO to) (NP (NP (JJ cold) (NN air)) (PRN (-LRB- -LRB-) (NP (CD 4) (NNS degrees) (NN C)) (-RRB- -RRB-)))) (ADVP (RB (d twice))) (, ,) (NP-TMP (CD 30) (NN (exposure min))) (, ,) (PP (IN for) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 80) (NNS exposures))))))) (. .))
(S (S-COOD (S (NP-SBJ (DT The) (JJ T3-) (NNS subjects)) (VP (VBD received) (NP (NP (NN placebo)) (PRN (-LRB- -LCB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 8)))) (-RRB- -RCB-))))) (CC and) (S (NP-SBJ (DT the) (ADJP (JJ T3+)) (NNS subjects)) (VP (VBD received) (NP (NP (CD T3)) (PRN (-LRB- -LRB-) (NP (CD 30) (NN (d micrograms))) (-RRB- -RRB-)) (PRN (-LRB- -LCB-) (S (NP-SBJ (NN n)) (VP (JJ =) (NP-PRD (CD 8)))) (-RRB- -RCB-)))))) (PP (IN in) (NP (DT a) (JJ double-blind) (NN fashion))) (. .))
(S (NP-SBJ-40 (JJ Mononuclear) (NNS leukocytes)) (VP (VBD were) (VP-COOD (VP (VBN isolated) (NP (-NONE- *-40)) (PP (IN from) (NP (JJ peripheral) (NN blood))) (SBAR-TMP-101 (IN before) (S (NP-SBJ-COOD (NP (DT the) (JJ cold) (NN exposure)) (CC and) (NP (NN drug) (NNS regimen))) (VP (VBD began))))) (, ,) (CC and) (RB then) (VP (PP-TMP=101 (IN after) (NP (QP (DT every) (CD 20)) (NNS exposures)))))) (. .))
(S (NP-SBJ-41 (NP (DT The) (NP-COOD (NP (NP (NN dissociation) (NN constant)) (PRN (-LRB- -LRB-) (NP (NN Kd)) (-RRB- -RRB-))) (CC and) (NP (NP (NN maximum) (NN binding) (NN capacity)) (PRN (-LRB- -LRB-) (NP (NN MBC)) (-RRB- -RRB-))))) (PP (IN of) (NP (DT the) (NN NT3R) (NNS values)))) (VP (VBD were) (VP (NN log) (VBN transformed) (NP (-NONE- *-41)) (S (NP-SBJ (-NONE- *)) (VP (TO to) (VP (VB minimize) (NP (JJ between-subject) (NN variability))))))) (. .))
(S (PP (IN In) (NP (DT the) (JJ T3+) (NN group))) (, ,) (NP-SBJ-COOD (NP (NP (NN serum) (VBP total) (NN thyroxine)) (PRN (-LRB- -LRB-) (NP (NN TT4)) (-RRB- -RRB-))) (, ,) (NP (NP (JJ free) (NN T4)) (PRN (-LRB- -LRB-) (NP (NN FT4)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NN TSH))) (VP (VBD were) (ADJP-PRD (ADJP (NP (QP (RB approx) (CD 50)) (NN %)) (JJR lower)) (PP (IN than) (NP-COOD (CC both) (NP (JJ basal) (NP (-NONE- *?*))) (CC and) (NP (NNS T3-values)))))) (. .))
(S (S-COOD (S (NP-SBJ (DT The) (NN log10Kd)) (VP (VBD increased) (NP (QP (CD 0.304) (CC (- +)) (CD 0.139))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.04)))) (-RRB- -RRB-)))) (CC and) (S (NP-SBJ (DT the) (NN log10MBC)) (VP (VBD increased) (NP (QP (CD 0.49) (CC (- +)) (CD 0.10))) (PRN (-LRB- -LRB-) (S (NP-SBJ (NN p)) (NP-PRD (QP (JJR &lt;) (CD 0.001)))) (-RRB- -RRB-))))) (PP (IN in) (NP (DT the) (JJ T3+) (NNS subjects))) (PP (VBN compared) (PP (TO to) (NP (NN baseline)))) (. .))
(S (NP-SBJ (NP (DT This) (NN change)) (PP (IN in) (NP (NN MBC)))) (VP (VBZ represents) (NP-COOD (NP (NP (DT a) (CD 311) (NN %) (NN increase)) (PP (IN in) (NP (DT the) (NN MBC))) (PP (IN over) (NP (NN baseline)))) (CC and) (NP (NP (DT a) (JJ fivefold) (NN increase)) (PP (IN over) (NP (JJ placebo-treated) (NNS subjects)))))) (. .))
(S (NP-SBJ (DT The) (JJ T3-) (NN group)) (VP (VBD showed) (NP (NP (DT no) (NN change)) (PP (IN in) (NP (NN MBC)))) (PP (IN over) (NP (DT the) (NN study)))) (. .))
(S (NP-SBJ (DT These) (NNS results)) (VP (VBP describe) (PP-TMP (IN for) (NP (DT the) (JJ first) (NN time))) (NP (NP (DT the) (JJ rapid) (NN modulation)) (PP (IN of) (NP (DT the) (NN NT3R))) (PP (IN in) (NN response) (TO to) (NP (NP (DT the) (JJ combined) (NN influence)) (PP (IN of) (NP-COOD (NP (JJ cold) (NN exposure)) (CC and) (NP (VBN reduced) (VBG circulating) (NP-COOD (NP (NN T4)) (CC and) (NP (NN TSH)))))))))) (. .))
